Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study by Junichiro Yuda, Noriko Doki, Hiroshi Matsuoka, Takafumi Yokota, Akihiro Tomita, Naoto Takahashi, Itaru Matsumura, Kohmei Kubo, Tatsunori Goto, Keita Kirito, Akio Maki, Makoto Aoki, Alex Allepuz, Yosuke Minami

Get full text